Once-Weekly Oral Combo for HIV Maintains High Rates of Virologic Suppression

(MedPage Today) — A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic suppression compared with standard daily oral treatment in an open-label phase II trial.
In 104 virologically…